The average EPS estimate for Epizyme, Inc. (NASDAQ:EPZM) for the three months ending 2016-12-31 is given as $-0.6.
You find that 7 days ago, the average EPS estimate on the stock was $-0.6, while for the 30 days ago the average EPS estimate stood at $-0.6.
If you look back further, you see that the average EPS estimate for Epizyme, Inc. (NASDAQ:EPZM) 60 days ago was given as -0.6, while EPS estimate 90 days ago was quoted at $-0.6.
The change in the stock’s EPS estimate over the last 7 days works out to 0%.
EPS estimate revisions
Over the last 7 days, EPS estimates for Epizyme, Inc. (NASDAQ:EPZM) have been revised up 0 times. In the same period, the EPS estimate has been revised down 0 times.
In the last 30 days, the stock has had its EPS estimate revised up 3 and it has been revised up 3 times over the last 60 days.
Up revisions in the last 90 days are 3 and up revisions in the last 120 days are 3.
But for the last 18 days, the company has seen its EPS revised up 2 times, offset by 0 down revisions in the same period.
The down revisions of EPS in last 30, 60, 90 and 120 days were 1, 1, 1 and 1.
What About EPS Surprises
Analysts predicted EPS of $-0.6 for Epizyme, Inc. (NASDAQ:EPZM) for the period ended 2. But the company ended up posting actual EPS of $-0.49 on 2016-08-08. The EPS estimate cited was worked out based on 5 estimates that analysts had issued on the stock.
Therefore, Epizyme, Inc. (NASDAQ:EPZM) posted EPS surprise of $0.01 per share in dollar terms, which works out to 2%. The standard deviation of the actual EPS reported by the company and the average EPS estimate immediately before the earnings were released works out to $0.06.
Quarterly Sales Estimates
For the fiscal year 2016, the mean and median annual sales estimates for the company are given as $0.643 and $0.5. The estimates are based on the projections of 4 analysts.
So far, the highest annual sales estimate for Epizyme, Inc. (NASDAQ:EPZM) stands at$1.1. That compares with the lowest annual sales estimate of $0.473. Calculating the standard deviation of the extreme annual sales estimates leads you to 0.304%.
Annual sales estimate adjustments
In the last 7 days, 4 analysts have raised their annual sales estimates for the company. But over the same period, 4 analysts have trimmed their annual sales estimates.
With that, you find that the percentage change in mean annual sales estimate in the last 7 days works out to 0%.
Over the last one month, though, 4 analysts moved to raise their sales estimates for Epizyme, Inc. (NASDAQ:EPZM). That compares with 4 analysts who cut their sales estimate for the company in the same period. That leads you to -0.771% as the mean sales estimate change over the last one month.
If you look back further, you see that over the last three months, 4 analysts have moved raise their sales estimates Epizyme, Inc. (NASDAQ:EPZM). That offset by 4 analysts who in the same period lowered their sales estimates for the stock. That works out to percentage change in mean sales estimate of -0.771% over a period of three months.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...